Q-omics provides the consensus-scored HEBP2P1 profile across patient tissues and cancer cell-line models. HEBP2P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, HEBP2P1 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, HEBP2P1 RNA expression shows 11,271 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight THCA, STAD, and HNSC as cancer lineages where HEBP2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEBP2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEBP2P1 survival associations across molecular data types. HEBP2P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEBP2P1 RNA expression–survival associations across cancer types. High HEBP2P1 expression shows unfavorable associations in THCA, COAD, UCEC, LUAD, MESO and KIRC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for HEBP2P1 RNA expression.
This table summarizes HEBP2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HEBP2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEBP2P1 shows higher tumor expression in STAD, COAD, LUSC and HNSC. The STAD box plot shows higher HEBP2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.174, t-test p = .031).
This table shows molecular features associated with HEBP2P1 in patient tissues and cancer cell lines. In patient samples, HEBP2P1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
